Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.80 |
| ▸ | TYMS | P04818 | 3/20 | 0.78 |
| ▸ | TK1 | P04183 | 3/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymidine Monophosphate SCHEMBL8139411 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL21257 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL29463974 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL2037921 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL8366987 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL16280929 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL18785041 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL7876022 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL3984895 | 1.00 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL8886065 | 1.00 | POLB (0.80) | POLBTYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230304055-A1 | ONE-POT CELL-FREE GLYCOSYLATION PROCESS | C-LECTA GMBH (DE) | 2023-09-28 | — | — | US | claimed |
| EP-4176070-A1 | ONE-POT CELL-FREE GLYCOSYLATION PROCESS | c-LEcta GmbH (DE) | 2023-05-10 | — | — | EP | claimed |
| US-20230304055-A1 | ONE-POT CELL-FREE GLYCOSYLATION PROCESS | C-LECTA GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| EP-4176070-A1 | ONE-POT CELL-FREE GLYCOSYLATION PROCESS | c-LEcta GmbH (DE) | 2023-05-10 | — | — | EP | disclosed |
| WO-2023043830-A1 | COMBINATION THERAPIES TO TREAT VIRAL INFECTIONS | Clear Creek Bio, Inc. (US) | 2023-03-23 | — | — | WO | disclosed |
| US-20220411463-A1 | MATE AND SEPARATE: A CONVENIENT AND GENERAL METHOD FOR THE SEPARATION AND PURIFICATION OF TARGET MOLECULES FROM BIOLOGICAL MEDIA BY PHASE TRANSITION OF PEGYLATED RECOGNITION AGENTS. | KARIMIAN, KHASHAYAR (IR) | 2022-12-29 | — | — | US | disclosed |
| WO-2020188323-A1 | MATE AND SEPARATE: A CONVENIENT AND GENERAL METHOD FOR THE SEPARATION AND PURIFICATION OF TARGET MOLECULES FROM BIOLOGICAL MEDIA BY PHASE TRANSITION OF PEGYLATED RECOGNITION AGENTS. | KARIMIAN KHASHAYAR (IR) | 2020-09-24 | — | — | WO | disclosed |
| US-10420761-B2 | Allosteric inhibitors of thymidylate synthase | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-10420761-B2 | Allosteric inhibitors of thymidylate synthase | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160067240-A1 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067240-A1 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067240-A1 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2014145386-A2 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION INCORPORATED (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411463-A1 | MATE AND SEPARATE: A CONVENIENT AND GENERAL METHOD FOR THE SEPARATION AND PURIFICATION OF TARGET MOLECULES FROM BIOLOGICAL MEDIA BY PHASE TRANSITION OF PEGYLATED RECOGNITION AGENTS. | TPR, STAMBP, NASP | POLB 172/4885TYMS 241/4885TK1 263/4885 |
| US-10420761-B2 | Allosteric inhibitors of thymidylate synthase | MCL1, GLS, TYMS | POLB 968/4885TYMS 3/4885TK1 31/4885 |
| US-20160067240-A1 | NOVEL ALLOSTERIC INHIBITORS OF THYMIDYLATE SYNTHASE | GLS, MCL1, TYMS | POLB 943/4885TYMS 3/4885TK1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.